Trial Profile
A Phase I Dose Escalation Study of the HIV Protease Inhibitor, Nelfinavir, Given Concomitantly With Radical Radiotherapy (RT) for the Treatment of Non-Small Cell Lung Cancer (NSCLC).
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Apr 2013
Price :
$35
*
At a glance
- Drugs Nelfinavir (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms NelfLung
- 08 Oct 2011 New trial record